Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Marizomib for central nervous system-multiple myeloma.

Ashraf Badros1, Zeba Singh1, Binod Dhakal2

  • 1M&S Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD, USA.

British Journal of Haematology
|April 8, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Rehabilitation Utilization After CAR T-Cell Therapy.

Transplantation and cellular therapy·2026
Same author

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

HemaSphere·2026
Same author

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Coupling dead cell recognition to Fcγ receptors augments anticancer immunity.

Nature cancer·2026
Same author

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.

Blood cancer journal·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026

Marizomib shows promise for treating central nervous system-multiple myeloma (CNS-MM), a rare cancer complication. These case studies suggest marizomib may be a viable therapeutic option for patients with CNS-MM.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Pharmacology

Background:

  • Central nervous system-multiple myeloma (CNS-MM) is a rare, aggressive complication of multiple myeloma with limited treatment options.
  • Marizomib, a marine-derived proteasome inhibitor, has shown activity in relapsed-refractory multiple myeloma (RRMM) and malignant glioma.
  • There is a significant unmet need for effective therapies targeting CNS-MM.
Keywords:
central nervous system relapseclinical studiesmarizomibmultiple myeloma

Related Experiment Videos